Novel selective Cdc42 inhibitor, suppressing primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity

Novel weak PAR2 antagonist

Novel covalent ERK1/2 inhibitor

Novel tankyrase inhibitor, enhancing irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

Novel potent EphB4 inhibitor

Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist

Novel orally bioavailable inhibitor of Hedgehog signaling

Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist

Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist

Second Generation

Cyclooxygenase Inhibitor;

Novel integrin-binding peptide, inhibiting hepatocyte growth factor (HGF) signaling through Met-integrin interactions, also being an antiangiogenic agent by reducing phosphorylation of VEGR2, IGFR, and PDGFR, stabilizing vessels by disrupting α5β1 signali

Novel highly potent and orally bioavailable Axl inhibitor

Novel potent dual ERK5 and BRD4 inhibitor

Novel potent and selective ERK5 inhibitor

Novel dual ERK5 and BRD4 inhibitor

Highly specific JNK inhibitor #212121; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0

Zn -dependent inhibitor of human plasma Lp-PLA2

Novel potent dual inhibitor of Ax1 and Mer

Novel specific inhibitor of HIV-1 entry through interaction with the Env spike by virtue of the incorporation of a guandinium group

Novel PDE4 inhibitor

The first potent and selective αvβ5 integrin inhibitor

Novel potent and selective αvβ3 integrin inhibitor

Potent broad spectrum antibacterial agent, particularly against drug-resistant Staphylococcus pathogens

Novel cytosolic phospholipase A2 group IVA (cPLA2α) inhibitor, displaying potent anti-inflammatory activity and disease-modifying properties in cellular and in vivo models

Natural potent antienterovirus D68 (anti-EV-D68) agent

Cancer chemoprevebtive agent

Novel antistaphyloccocal agent, attenuating inhibition of hERG potassium channel current

Novel angiotensin-(1-7) Mas receptor agonist

Novel non-peptide Ang-(1-7) mimetic, inhibiting perivascular inflammation, through the reduction of chemokine expression in pVAT, as well as through direct actions on monocytes/macrophages inhibiting their activation